{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T03:09:52Z","timestamp":1777432192726,"version":"3.51.4"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.jpba.2023.115759","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T13:22:38Z","timestamp":1696944158000},"page":"115759","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["In silico and in vitro human metabolism of IOX2, a performance-enhancing doping agent"],"prefix":"10.1016","volume":"238","author":[{"given":"Omayema","family":"Taoussi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prince Sellase","family":"Gameli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diletta","family":"Berardinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Paolo","family":"Busard\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasio","family":"Tini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3332-9518","authenticated-orcid":false,"given":"Jeremy","family":"Carlier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2023.115759_bib1","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jpba.2023.115759_bib2","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/dta.3010","article-title":"A validated method for the quantification of IOX-2, a potent prolyl hydroxylase inhibitor in equine urine and plasma using liquid chromatography-high-resolution mass spectrometry","volume":"13","author":"Mikhail","year":"2021","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2023.115759_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/cells11030391","article-title":"HIF-1\u03b1 stabilization in flagellin-stimulated human bronchial cells impairs barrier function","volume":"11","author":"Ramirez-Moral","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jpba.2023.115759_bib4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1126\/science.1059817","article-title":"HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing","volume":"292","author":"Ivan","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.jpba.2023.115759_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/nano12010163","article-title":"Liposomal PHD2 inhibitors and the enhanced efficacy in stabilizing HIF-1\u03b1","volume":"12","author":"Jian","year":"2022","journal-title":"Nanomater. (Basel)"},{"key":"10.1016\/j.jpba.2023.115759_bib6","unstructured":"World Anti-Doping Code International Standard Prohibited List 2023, 2023. \u3008https:\/\/www.wada-ama.org\/sites\/default\/files\/2022\u201309\/2023list_en_final_9_september_2022.pdf\u3009 (accessed June 22, 2023)."},{"key":"10.1016\/j.jpba.2023.115759_bib7","unstructured":"Executive Summary, World Anti-Doping Agency, 2021. \u3008https:\/\/www.wada-ama.org\/sites\/default\/files\/2023\u201301\/2021_anti-doping_testing_figures_en.pdf\u3009 (accessed June 22, 2023)."},{"key":"10.1016\/j.jpba.2023.115759_bib8","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00204-015-1549-y","article-title":"Impairment of hypoxia-induced HIF-1\u03b1 signaling in keratinocytes and fibroblasts by sulfur mustard is counteracted by a selective PHD-2 inhibitor","volume":"90","author":"Deppe","year":"2016","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.jpba.2023.115759_bib9","unstructured":"Synthetic Doping Agent Detected in Two Standardbreds, (2020). \u3008https:\/\/www.thoroughbreddailynews.com\/synthetic-doping-agent-detected-in-two-standardbreds\/\u3009 (accessed June 22, 2023)."},{"key":"10.1016\/j.jpba.2023.115759_bib10","unstructured":"World Anti-Doping Code International Standard Prohibited List 2022, 2022. \u3008https:\/\/www.wada-ama.org\/sites\/default\/files\/resources\/files\/2022list_final_en.pdf\u3009 (accessed June 22, 2023)."},{"key":"10.1016\/j.jpba.2023.115759_bib11","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1002\/dta.2914","article-title":"Implementation of the HIF activator IOX-2 in routine doping controls - pilot study data","volume":"12","author":"G\u00f6rgens","year":"2020","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2023.115759_bib12","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jpba.2018.05.007","article-title":"Synthetic cannabinoid BB-22 (QUCHIC): human hepatocytes metabolism with liquid chromatography-high resolution mass spectrometry detection","volume":"157","author":"Carlier","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2023.115759_bib13","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11419-018-0448-3","article-title":"Sensitive quantification of BB-22 and its metabolite BB-22 3-carboxyindole, and characterization of new metabolites in authentic urine and\/or serum specimens obtained from three individuals by LC-QTRAP-MS\/MS and high-resolution LC-Orbitrap-MS\/MS","volume":"37","author":"Minakata","year":"2019","journal-title":"Forensic Toxicol."},{"key":"10.1016\/j.jpba.2023.115759_bib14","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00204-022-03289-z","article-title":"In silico, in vitro, and in vivo human metabolism of acetazolamide, a carbonic anhydrase inhibitor and common \u201cdiuretic and masking agent\u201d in doping","volume":"96","author":"Busard\u00f2","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.jpba.2023.115759_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/metabo13010092","article-title":"\u03b1-Methyltryptamine (\u03b1-MT) metabolite profiling in human hepatocyte incubations and postmortem urine and blood","volume":"13","author":"Malaca","year":"2023","journal-title":"Metabolites"},{"key":"10.1016\/j.jpba.2023.115759_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1002\/cpt.534","article-title":"Approaches, challenges, and advances in metabolism of new synthetic cannabinoids and identification of optimal urinary marker metabolites","volume":"101","author":"Diao","year":"2017","journal-title":"Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2023.115759_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.3389\/fchem.2019.00109","article-title":"New synthetic cannabinoids metabolism and strategies to best identify optimal marker metabolites","volume":"7","author":"Diao","year":"2019","journal-title":"Front Chem."},{"key":"10.1016\/j.jpba.2023.115759_bib18","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/bioinformatics\/btz695","article-title":"NERDD: a web portal providing access to in silico tools for drug discovery","volume":"36","author":"Stork","year":"2020","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jpba.2023.115759_bib19","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1021\/acs.chemrestox.0c00224","article-title":"GLORYx: prediction of the metabolites resulting from phase 1 and phase 2 biotransformations of xenobiotics","volume":"34","author":"De Bruyn Kops","year":"2021","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.jpba.2023.115759_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2022.123162","article-title":"3F-\u03b1-pyrrolydinovalerophenone (3F-\u03b1-PVP) in vitro human metabolism: multiple in silico predictions to assist in LC-HRMS\/MS analysis and targeted\/untargeted data mining","volume":"1193","author":"Carlier","year":"2022","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2023.115759_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2021.122740","article-title":"In silico prediction, LC-HRMS\/MS analysis, and targeted\/untargeted data-mining workflow for the profiling of phenylfentanyl in vitro metabolites","volume":"235","author":"Di Trana","year":"2021","journal-title":"Talanta"},{"key":"10.1016\/j.jpba.2023.115759_bib22","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1080\/17425255.2022.2166826","article-title":"Biomarkers of 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) intake identified from human hepatocyte incubations","volume":"18","author":"Carlier","year":"2023","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.jpba.2023.115759_bib23","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1002\/dta.2202","article-title":"lmplementation of the prolyl hydroxylaseinhibitor roxadustat (FG-4592) and its mainmetabolites into routine doping controls","volume":"9","author":"Eichner","year":"2017","journal-title":"Drug Test. Anal."},{"key":"10.1016\/j.jpba.2023.115759_bib24","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1002\/dta.3000","article-title":"Metabolic studies of hypoxia-inducible factor stabilisers IOX2, IOX3 and IOX4 (in vitro) for doping control","volume":"13","author":"Philip","year":"2021","journal-title":"Drug Test. Anal."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523005289?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708523005289?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T09:29:31Z","timestamp":1760002171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708523005289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":24,"alternative-id":["S0731708523005289"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115759","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In silico and in vitro human metabolism of IOX2, a performance-enhancing doping agent","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2023.115759","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115759"}}